News

Gene Therapy for CMT1B Wins CMT Research Foundation Grant

The CMT Research Foundation has granted over $500,000 to help develop a gene therapy for Charcot-Marie-Tooth disease type 1B (CMT1B). The grant was awarded to Afrooz Rashnonejad, PhD, principal investigator at the Nationwide Children’s Hospital Center for Gene Therapy and a professor at the Ohio State University’s department of…

Global CMT Research Convention on Tap for Sept 16–17 in Cambridge, MA

Treatments for all types of Charcot-Marie-Tooth disease (CMT) will be the focus of the second annual Global CMT Research Convention, Sept. 16 and 17, in Cambridge, Massachusetts. Presented by the CMT Research Foundation, the event brings together patients, scientists, and biopharmaceutical companies to celebrate treatment advancements and the pioneers…

New Mutations in SLC12A6 Gene Tied to Several CMT Subtypes

Newly identified mutations in the SLC12A6 gene associated with several subtypes of Charcot-Marie-Tooth (CMT) disease have been found, according to a study in Japan. The mutations also affected the central nervous system (brain and spinal cord). The findings call for the need to screen for mutations in the SLC12A6 gene…

Theophylline Enhances Myelin Production in CMT1A Mice

Theophylline, a medication used to treat asthma and other respiratory conditions, promoted myelination — the process by which sheaths of myelin, a fatty substance, are produced around nerves to protect them — in a mouse model of Charcot-Marie-Tooth disease type 1 subtype A (CMT1A), a study shows. Treatment with…

Exercise-induced Irisin Hormone May Be Muscle Loss Biomarker

Blood levels of irisin, an exercise-induced muscle hormone, are significantly lower in people with Charcot-Marie-Tooth disease (CMT) and associate with muscle strength and quality, a small study shows. The findings suggest that this protein, previously shown to have protective effects against muscle wasting, may be a useful biomarker to…